ECAR-T is under clinical development by Chineo Med Beijing and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ECAR-T’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cellular immunotherapy is under development for the treatment of melanoma, malignant solid tumors, esophageal cancer, gastric cancer, pancreatic cancer, colorectal cancer and CD19 positive recurrent or refractory non-Hodgkin lymphoma. It is administered through intravenous and parenteral route. The drug candidate comprises of super circulating tumor infiltrating lymphocytes (ScTIL210).
For a complete picture of ECAR-T’s drug-specific PTSR and LoA scores, buy the report here.